Our mission is to deliver highly effective, off-the-shelf, allogeneic, natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Our established Manufacturing-First approach has enabled us to produce, store and ship our product candidates and make them accessible like traditional protein biologic therapies.

Our lead product candidate, AB-101, is an off-the-shelf NK cell therapy that is currently being studied in a Phase 1/2 trial with rituximab in patients with non-Hodgkins lymphoma (NHL).

We are also developing AB-201 and AB-202, our first two chimeric antigen receptor-NK (CAR-NK) product candidates, for which we plan to file investigational new drug applications (IND) in the second half of 2022 and in 2023, respectively. We are leveraging our proprietary platform and manufacturing capabilities to generate a broad pipeline of off-the-shelf NK cell therapeutic candidates for the treatment of hematologic malignancies and solid tumors.

We believe our Manufacturing-First approach positions us to supplant the patient-specific business model for autologous cell therapy by delivering high quality campaign-manufactured products with low cost of goods and off-the-shelf-availability at the point of care. We accomplish this by optimizing the sourcing and selection of healthy donor umbilical cord blood; utilizing a highly scaled proprietary NK cell expansion and cryopreservation process; and leveraging an established manufacturing infrastructure and cold chain logistics. Today, we have the capability to manufacture thousands of doses of allogeneic NK cell drug product from a single cord blood unit, cryopreserve the NK cell doses in an infusion-ready solution, store the product with long-term shelf life while retaining activity and viability, and deliver the product to the clinic for administration of repeat dosing in an out-patient setting.

(Note: Artiva Biotherapeutics, Inc. filed confidentially for an IPO on March 2, 2021; filed its S-1 on April 8, 2021, and most recently amended its S-1 with an S-1/A filing dated June 6, 2022. No terms have been filed yet, though, for this IPO.)